Co-Diagnostics (CODX) Stock Forecast, Price & News

Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

Is Co-Diagnostics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics or view top-rated stocks.

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 1,430,000 shares, a drop of 29.9% from the April 15th total of 2,040,000 shares. Based on an average trading volume of 356,600 shares, the short-interest ratio is presently 4.0 days.
View Co-Diagnostics' Short Interest.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Co-Diagnostics.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its earnings results on Thursday, May, 12th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.16. Co-Diagnostics had a trailing twelve-month return on equity of 32.20% and a net margin of 40.25%. During the same quarter in the previous year, the firm posted $0.26 earnings per share.
View Co-Diagnostics' earnings history.

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics issued an update on its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided earnings per share guidance of $0.170-$0.200 for the period, compared to the consensus estimate of $0.110. The company issued revenue guidance of $21 million-$22 million, compared to the consensus revenue estimate of $21.28 million.

What price target have analysts set for CODX?

3 Wall Street analysts have issued 1 year price objectives for Co-Diagnostics' stock. Their forecasts range from $12.00 to $14.00. On average, they expect Co-Diagnostics' share price to reach $13.00 in the next year. This suggests a possible upside of 158.4% from the stock's current price.
View analysts' price targets for Co-Diagnostics or view top-rated stocks among Wall Street analysts.

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:

• Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 69, Pay $1.02M)
• Mr. Brian L. Brown CPA, CFO & Company Sec. (Age 46, Pay $730.62k)
• Mr. Reed L. Benson, Gen. Counsel (Age 74, Pay $385.85k) (LinkedIn Profile)
• Dr. Brent C. Satterfield Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 45)
• Dr. Jesse Montgomery, Chief Scientific Officer
• Mr. Andrew Benson, Head of Investor Relations
• Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
• Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

Who are some of Co-Diagnostics' key competitors?

Some companies that are related to Co-Diagnostics include Cardiovascular Systems (CSII), UFP Technologies (UFPT), Orthofix Medical (OFIX), Surmodics (SRDX), SI-BONE (SIBN), Inovio Pharmaceuticals (INO), MiMedx Group (MDXG), Alpha Tau Medical (DRTS), Sight Sciences (SGHT), IRadimed (IRMD), Liquidia (LQDA), OraSure Technologies (OSUR), Nyxoah (NYXH), Anika Therapeutics (ANIK) and SeaSpine (SPNE).
View all of CODX's competitors.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.51%), Renaissance Technologies LLC (1.73%), BlackRock Inc. (1.44%), Advisor Resource Council (0.78%), Bank of New York Mellon Corp (0.67%) and Easterly Investment Partners LLC (0.42%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics.

Which institutional investors are selling Co-Diagnostics stock?

CODX stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Charles Schwab Investment Management Inc., Advisor Resource Council, Principal Financial Group Inc., Advisor Group Holdings Inc., Easterly Investment Partners LLC, Walleye Trading LLC, and Simplex Trading LLC. Company insiders that have sold Co-Diagnostics company stock in the last year include Eugene Durenard, and Reed L Benson.
View insider buying and selling activity for Co-Diagnostics or view top insider-selling stocks.

Which institutional investors are buying Co-Diagnostics stock?

CODX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., Acadian Asset Management LLC, Engineers Gate Manager LP, Bank of New York Mellon Corp, State of Tennessee Treasury Department, Qube Research & Technologies Ltd, and Prelude Capital Management LLC.
View insider buying and selling activity for Co-Diagnostics or or view top insider-buying stocks.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $5.03.

How much money does Co-Diagnostics make?

Co-Diagnostics has a market capitalization of $170.96 million and generates $97.89 million in revenue each year. The company earns $36.66 million in net income (profit) each year or $1.30 on an earnings per share basis.

How many employees does Co-Diagnostics have?

Co-Diagnostics employs 101 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at (801) 438-1036 or via email at [email protected].